by Clinical Neuropsychologist | Friday, May 17, 2024 | Dementia
Abstract INTRODUCTION Plasma biomarkers of Alzheimer’s disease and related dementias predict global cognitive performance and decline over time; it remains unclear how they associate with changes in different dementia syndromes affecting distinct cognitive...
by Clinical Neuropsychologist | Friday, May 17, 2024 | Dementia
Abstract BACKGROUND Compromised autophagy, including impaired mitophagy and lysosomal function, plays pivotal roles in Alzheimer’s disease (AD). Urolithin A (UA) is a gut microbial metabolite of ellagic acid that stimulates mitophagy. The effects of UA’s...
by Clinical Neuropsychologist | Thursday, May 16, 2024 | Dementia
Abstract INTRODUCTION This study investigates the effect of apolipoprotein E (APOE) genotype on neurology plasma biomarkers in cognitively healthy Super-Seniors. METHODS Three hundred seventy plasma specimens from Super-Senior participants ≥ 85 years old, who have...
by Clinical Neuropsychologist | Monday, May 13, 2024 | Dementia
Abstract INTRODUCTION MODEL-AD (Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease) is creating and distributing novel mouse models with humanized, clinically relevant genetic risk factors to capture the trajectory and progression of...
by Clinical Neuropsychologist | Thursday, May 9, 2024 | Dementia
Abstract INTRODUCTION We explored the variations of blood biomarkers of Alzheimer’s disease (AD) by chronic diseases and systemic inflammation. METHODS We explored the association of AD blood biomarkers with chronic diseases and systemic inflammation...